Table 1. EGFR and mTOR pathway immunostaining in 107 SCLC tissue specimens.
| Immunohistochemical staining | Negative | Weak | Strong |
|---|---|---|---|
| EGFR | 67 (63%) | 24 (22%) | 16 (15%) |
| p-ERK | 93 (87%) | 8 (7%) | 6 (6%) |
| p-AKT | 81 (76%) | 20 (19%) | 6 (5%) |
| p-mTOR | 48 (45%) | 41 (38%) | 18 (17%) |
| p-p70s6K | 10 (9%) | 40 (38%) | 57 (53%) |
Abbreviations: EGFR=epidermal growth factor receptor; mTOR=mammalian target of rapamycin; p-AKT=phosphorylated AKT; p-ERK=phosphorylated extracellular signal-regulated kinase; SCLC=small cell lung cancer.